{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344623","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-08-11T20:08:50+00:00","discovered_at":"2026-08-11T20:10:01.473027+00:00","generated_at":"2026-08-11T20:10:07.835664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inhibikase Q2 net loss widens to $19.6M; Phase 3 PAH trial advances with $50M financing","bullets":["Q2 2026 net loss $19.6M ($0.11/share) vs $9.9M loss in Q2 2025; R&D spend up to $13.4M from $5.3M.","Cash, equivalents, and marketable securities $159.0M at June 30, 2026; plus $50M gross from 25M shares sold to RA Capital in July 2026.","FDA granted Orphan Drug Designation for IKT-001 in July 2026; Phase 3 IMPROVE-PAH approvals in 26 countries, 43 sites initiated.","Company expects existing and new capital to fund operations through Part B topline data readout, assuming warrant exercise.","Pre-clinical/Phase 1 data at ATS showed improved GI profile vs imatinib and 18-fold lower c-Kit inhibition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344623","json":"https://secwatch.observer/filing/0001193125-26-344623.json","markdown":"https://secwatch.observer/filing/0001193125-26-344623.md","text":"https://secwatch.observer/filing/0001193125-26-344623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/0001193125-26-344623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/d134059d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:10:07.835664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}